Pharming Group (PHARM) Corporate presentation summary

Strategic vision and commercial foundation

• Aims to become a leading global rare disease company with a diverse portfolio and strong presence in large markets.

• Leverages proven clinical development, supply chain, and commercial infrastructure.

• RUCONEST and Joenja serve as commercial cornerstones, providing durable cash flow and growth momentum.

Product portfolio and pipeline highlights

• RUCONEST is approved for acute hereditary angioedema (HAE), showing rapid, reliable attack resolution and a resilient patient base.

• Joenja (leniolisib) is approved for APDS, with ongoing expansion into pediatric and international markets and Phase II studies in PIDs/CVID.

• Napazimone (KL1333) is in pivotal trials for mtDNA mitochondrial disease, with positive interim analysis and >$1B revenue potential.

RUCONEST performance and clinical data

• 97% of acute HAE attacks resolved with one dose; median time to complete resolution is 4.5 hours.

• Demonstrates significantly faster attack resolution compared to sebetralstat, with 93.4% of attacks resolved within 24 hours.

• Q2 2026 revenue was $72.3M, down 10% YoY but up 24% sequentially, with stabilization and growth expected by year-end.